Karyopharm Therapeutics Inc. (KPTI) earnings
Quarterly results of Karyopharm Therapeutics Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) Karyopharm Therapeutics Inc. reported revenue of $33.4M (-11.9% on the same quarter a year earlier) and a net loss of $67M.
Diluted earnings per share were -$2.32.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | $33.4M | -11.9% | -$67M | -$2.32 |
| Q1 FY2026 | $35.1M | +16.8% | -$22.4M | -$1.24 |
| Q4 FY2025 | $34.1M | +11.6% | -$102.2M | - |
| Q3 FY2025 | $44M | +13.6% | -$33.1M | -$3.82 |
| Q2 FY2025 | $37.9M | - | -$37.3M | -$4.32 |
| Q1 FY2025 | $30M | - | -$23.5M | -$2.77 |
| Q4 FY2024 | $30.5M | - | -$30.8M | - |
| Q3 FY2024 | $38.8M | - | -$32.1M | -$3.85 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
What were Karyopharm Therapeutics Inc.'s latest quarterly results?
For Q2 FY2026, which ended June 30, 2026, Karyopharm Therapeutics Inc. reported revenue of $33.4M and a net loss of $67M. The figures come from its filing with the SEC.
Is Karyopharm Therapeutics Inc.'s revenue growing?
Revenue in Q2 FY2026 was $33.4M, down 11.9% from $37.9M in the same quarter a year earlier.
Get an email when KPTI reports
Follow KPTI and we email you its next results the day they are filed, with the numbers explained.